| 摘要 |
The purpose of the present invention is to provide a method for easily determining the risk of developing primary central nervous system lymphoma, and a composition for treating primary central nervous system lymphoma. The present invention solves the above problem through: a method for determining the risk of a human subject developing primary central nervous system lymphoma, wherein the method includes a step for detecting mutant variants of GRB2 and/or MYD88, or nucleic acids that encode these mutant variants, from a sample derived from the subject, and a step for determining that there is a high risk of the subject developing primary central nervous system lymphoma when the abovementioned mutant variants or nucleic acids encoding the mutant variants are detected; and a composition for treating primary central nervous system lymphoma in a human subject, wherein the composition includes rituximab, or an agent for inhibiting the activity of GRB2 and/or a downstream signaling factor thereof, in the MAPK pathway, taking the abovementioned mutant variants to be the cause of primary central nervous system lymphoma. |
